It would really depend on the valuation for the dual listing. If...

It would really depend on the valuation for the dual listing. If it's higher than ASX valuation we could see some parity or maybe not!
The markets overseas don't always align.

Examples of this would be MSB with US valuation at $7-8B while the ASX valuation is only $2-3B. So rougly 3-3.5X difference. Another thing to compare is there is currency exchange to account for between AUD and USD, for MSB.

Which is roughly 5 times difference when converting USD to AUD. But that's based on the American Depositary Receipt (ADR) program facility trading on the NASDAQ market in the United States. Each Mesoblast ADR is equivalent to 5 ordinary shares of Mesoblast traded on the ASX.

Fingers crossed we see some upside! Depends on the structure of this dual listing.